This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "peripheral_axonal_degeneration#Distal Axonal Degeneration and Demyelination"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their context. Key disorder-specific substitutions: diabetic/metabolic neuropathy substitutes hyperglycemia and dyslipidemia at the trigger node; Charcot-Marie-Tooth substitutes myelin or gap-junction gene mutations and emphasizes the Schwann cell (CL:0002573) demyelinating arm; chemotherapy-induced neuropathy substitutes microtubule- or mitochondria-targeting antineoplastic agents and emphasizes the axonal-transport and mitochondrial-dysfunction amplifier; inflammatory/autoimmune neuropathy substitutes humoral or cell-mediated attack on axons and myelin. Predominantly axonal disorders may omit the Schwann cell demyelination component, and predominantly demyelinating disorders emphasize it; both converge on the length-dependent nerve-fiber dysfunction node.
Insult to Peripheral Neurons and Schwann Cells
trigger
Metabolic, genetic, toxic, or inflammatory insults injure peripheral sensory and motor neurons and the Schwann cells that ensheath their axons. The initiating lesion varies by disorder (hyperglycemia and dyslipidemia in diabetic neuropathy, myelin or gap-junction gene mutations in inherited neuropathy, microtubule- or mitochondria-targeting drugs in chemotherapy-induced neuropathy, autoantibody or cell-mediated attack in inflammatory neuropathy), but the downstream response converges on a shared program of cellular stress in peripheral neurons and glia.
Downstream
-
Axonal Transport Impairment and Mitochondrial Dysfunction
Show evidence (2 references)
"Diabetic peripheral neuropathy (DPN), the most common microvascular complication, is length-dependent damage to peripheral nerves."
Establishes the prototypical metabolic insult (diabetes) as length-dependent damage to peripheral nerves, the generic trigger state for this module. Evidence source is OTHER because this is a review synthesizing multiple study types.
"Despite the existence of a blood-nerve barrier, both humoral and cellular immunity can be directed against peripheral axons and myelin."
Demonstrates an alternative initiating lesion, immune-mediated attack on peripheral axons and myelin, that converges on the same peripheral neuron/Schwann cell injury. Evidence source is OTHER because this is a review of autoimmune peripheral neuropathies.
Axonal Transport Impairment and Mitochondrial Dysfunction
amplifier
Injured peripheral neurons exhibit disrupted axonal transport, mitochondrial structural and bioenergetic dysfunction, and increased oxidative stress. Because long peripheral axons depend on efficient transport of mitochondria and other cargo over great distances, this bioenergetic failure preferentially compromises the distal ends of the longest fibers and amplifies the initial insult toward overt degeneration.
Downstream
-
Distal Axonal Degeneration and Demyelination
Show evidence (2 references)
"many chemotherapeutic agents cause mitochondrial injury in the peripheral sensory nerves by disrupting mitochondrial structure and bioenergetics, increasing nitro-oxidative stress and altering mitochondrial transport, fission, fusion and mitophagy."
Directly links mitochondrial structural/bioenergetic injury, oxidative stress, and disrupted mitochondrial transport in peripheral sensory nerves. Evidence source is OTHER because this is a mini-review synthesizing preclinical and clinical data.
"One prominent change induced by chemotherapeutic agents involves the disruption of neuronal cytoskeletal architecture and axonal transport dynamics largely influenced by the interference of microtubule stability in peripheral neurons."
Confirms impaired axonal transport via cytoskeletal/microtubule disruption as a conserved amplifying mechanism in peripheral neurons. Evidence source is OTHER because this is a review.
Distal Axonal Degeneration and Demyelination
central effector
Sustained transport failure, mitochondrial dysfunction, and oxidative stress drive degeneration of the distal axon, frequently accompanied by Schwann cell demyelination. In predominantly axonal neuropathies the axon degenerates directly; in predominantly demyelinating neuropathies (e.g., demyelinating Charcot-Marie-Tooth disease) impaired Schwann cell-axon interactions and loss of myelin precede secondary axonal loss, but axonal degeneration is ultimately required for clinical symptoms. This is the central effector step converging across disorders.
Downstream
-
Length-Dependent Nerve Fiber Dysfunction
Show evidence (3 references)
"CMT1, CMT4, and CMTX1 are primarily demyelinating neuropathies, axonal degeneration is necessary for symptoms to develop. Schwann cell-axon interactions are impaired in the pathogenesis of demyelinating CMT."
Establishes the demyelination arm (impaired Schwann cell-axon interactions and myelin loss) and that axonal degeneration is ultimately required for symptoms, the central effector convergence. Evidence source is OTHER because this is a review.
"The pathophysiological processes are multi-factorial and involve oxidative stress, apoptotic mechanisms, altered calcium homeostasis, axon degeneration and membrane remodeling as well as immune processes and neuroinflammation."
Confirms axon degeneration alongside apoptotic mechanisms and oxidative stress as core processes in a toxic (chemotherapy-induced) neuropathy. Evidence source is OTHER because this is a review.
"the toxic effects on soma and axons were evaluated by an AI model with neurite images. Significant toxicity was detected in positive drugs and could be classified by different effects on soma or axons, suggesting that the current method provides an effective evaluation of chemotherapy-induced..."
New Approach Methodology (NAM) evidence: a human iPSC-derived sensory-neuron microphysiological system (MPS) combined with morphological deep learning recapitulates chemotherapy-induced distal axon (and soma) degeneration in vitro, giving human-cell-based support for this module's central axonal-degeneration effector step in toxic neuropathy without an animal model. Neurofilament light chain expression changes in the device also agreed with clinical reports. Evidence source is IN_VITRO because the finding comes from an iPSC-derived neuron culture system.
Length-Dependent Nerve Fiber Dysfunction
effector
Degeneration and demyelination of the longest axons cause loss of conduction in sensory and motor nerve fibers in a length-dependent distribution, so that the distal extremities (feet before hands) are affected first. The result is failed transmission of sensory, motor, and autonomic signals along the most vulnerable peripheral fibers.
Show evidence (2 references)
"CIPN is characterized by a substantial loss of primary afferent sensory axonal fibers leading to sensory disturbances in patients."
Demonstrates loss of sensory nerve-fiber function as the consequence of axonal degeneration. Evidence source is OTHER because this is a review.
"it can be viewed as a state of impaired metabolism and bioenergetics failure operating against the backdrop of long peripheral nerve axons supported by glia. This unique peripheral nerve anatomy and the injury consequent to T2D underpins the distal-to-proximal symptomatology of DPN."
Directly ties the vulnerability of long peripheral axons to the distal-to-proximal, length-dependent pattern of nerve-fiber dysfunction. Evidence source is OTHER because this is a review.
Peripheral Neuropathy
consequence
The convergent outcome is the clinical phenotype of peripheral neuropathy: distal sensory loss and numbness, neuropathic pain, and motor weakness, typically in a symmetric glove-and-stocking distribution reflecting the length-dependent degeneration of the longest peripheral nerve fibers. The relative contribution of sensory, motor, and autonomic deficits varies by underlying disorder, but the convergent phenotype is length-dependent peripheral nerve dysfunction.
Show evidence (2 references)
"chemotherapy-induced peripheral neuropathy presents as deficits in sensory, motor, and autonomic function which develop in a glove and stocking distribution due to preferential effects on longer axons."
Directly describes the clinical phenotype: sensory, motor, and autonomic deficits in a length-dependent glove-and-stocking distribution, the defining consequence of this module. Evidence source is OTHER because this is a review.
"The accumulation of abnormal and dysfunctional mitochondria in sensory neurons are linked to axonal growth defects resulting in the loss of intraepidermal nerve fibers in the hands and feet"
Connects the upstream mitochondrial/axonal mechanism to distal sensory nerve-fiber loss in the hands and feet, the clinical hallmark of peripheral neuropathy. Evidence source is OTHER because this is a mini-review.